-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Pelthos Therapeutics, Lowers Price Target to $59

Benzinga·11/13/2026 15:39:43
Listen to the news
Oppenheimer analyst Jeff Jones maintains Pelthos Therapeutics (AMEX:PTHS) with a Outperform and lowers the price target from $64 to $59.